Start Date
December 31, 2012
Primary Completion Date
November 30, 2013
Study Completion Date
November 30, 2014
Group 1 or Orencia treated group
Group 1 subjects will be given subcutaneous abatacept, 125 mg once a week upto 6 months.
Group 2 (DMARDS treated group)
Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept.
Univerity of California at Los Angeles, Los Angeles
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
University of California, Los Angeles
OTHER